0 item(s)
View cart
You have no items in your shopping cart.
Description
The recombinant humanized anti-CD3 monoclonal antibody is a full-length IgG1 molecule produced in CHO stable cells, engineered to specifically engage the extracellular Ig-like domain of CD3ε chain, thereby inducing TCR-CD3 complex crosslinking and ITAM domain phosphorylation to activate PLCγ1-PKC-MAPK signaling cascades that overcome T-cell activation thresholds.
As a pivotal T-cell activator in ex vivo expansion systems, it drives naive T-cell differentiation into effector/memory phenotypes and sustains CAR-T cell clonal expansion through metabolic synergy with IL-2/IL-15, while its glycoengineered Fc domain eliminates FcγR-mediated cytokine storm risks.
In adoptive immunotherapy development, this antibody dynamically modulates CD28 costimulatory signaling to enhance tumor antigen reactivity of TIL products, suppresses Treg expansion, and validates CD3-targeted bispecific antibody (CD3xTarget) functionality during NK cell activation/expansion, establishing a versatile platform for solid/hematologic tumor immunotherapy.
Production employs animal component-free media and chromatographic purification to ensure ultra-low endotoxin levels and host protein contamination control, meeting comprehensive quality standards across cell therapy applications.
Specifications
| Test Item | Specification | Results |
|---|---|---|
| Appearance | Should be a colorless and transparent liquid | Compliance |
| Identity | The electrophoretic bands should be consistent with the molecular weight of the product | Compliance |
| Visible Particle | Should be no visible particle | Compliance |
| pH | 6.5 – 7.5 | 7.3 |
| Concentration | 1.0 – 1.5 mg/mL | 1.04 mg/mL |
| Purity | >95.0% | 98.8% |
| Endotoxin | <0.01 EU/μg | <0.01 EU/μg |
| Mycoplasma | Should be negative | Negative |
| Sterility | No growth | No growth |
| Host Cell Protein Residues (CHO-HCP) | ≤100 ppm | 1.23 ppm |
| Host Cell (CHO) DNA Remains | ≤50 ng/mg | Not Detected |
| Biological Activity | Binding rate with Jurkat cells >90% | 97.3% |
Features
-
High-Specificity Targeting: Recognizes human CD3ε (epsilon) chain on T lymphocytes with high affinity, ideal for accurate T-cell identification.
-
Primary Monoclonal Antibody: Mouse-derived IgG1 primary antibody with consistent performance and lot integrity for research use.
-
Multi-Application Use: Validated for Flow Cytometry (FACS), Western Blot, ELISA, and Immunofluorescence, facilitating versatile immunological experiments.
-
Stable Formulation: Supplied in phosphate buffered saline (PBS) with stabilizers (BSA and sodium azide), optimized for long-term stability.
-
Research-Grade Quality: RUO (Research Use Only) antibody trusted by labs for immunophenotyping, T-cell activation studies, and cellular signaling research.
Applications
Flow Cytometry (FACS)
Flow Cytometry (FACS): Precise quantification and profiling of human CD3+ T cells in PBMCs and tissue samples.
Western Blot (WB)
Western Blot (WB): Detection of CD3ε protein expression in human cell lysates.
Immunofluorescence (IF)
Immunofluorescence (IF): Visualization of T-cell distribution and localization in cultured cells or tissue.
ELISA & Immunoassays
ELISA & Immunoassays: Analyzing CD3 presence or modulation in functional immunology studies.
T-Cell Activation & Signaling
T-Cell Activation & Signaling: Used in research to stimulate or monitor T-cell receptor interactions and downstream pathways.
Storage
Stable for up to 24 months when stored at 2-8°C under sterile condition.
Documents
References
-
Silvia M Bacot, Taylor A Harper, Rebecca L Matthews, Christie Jane Fennell, Adovi Akue, Mark A KuKuruga, Shiowjen Lee, Tao Wang, Gerald M Feldman. Exploring the Potential Use of a PBMC-Based Functional Assay to Identify Predictive Biomarkers for Anti-PD-1 Immunotherapy. Int J Mol Sci. 2020 Nov 27;21(23):9023.
-
Min Zhou, Jing Wang, Cui-Ping Li, Jing-Yan Xu, Bing Chen. Autologous Cytokine-Induced Killer Cell Immunotherapy for Patients with High-Risk Diffuse Large B Cell Lymphoma After the First Complete Remission. Onco Targets Ther. 2020 Jun 22;13:5879-5885.
Attention
For research and manufacturing purposes only.
When can I expect my order to ship?
Most orders are filled and shipped within 2-3 business days from the time they are received.
Our standard shipping usually take 2-5 days.
We also provide express shippping for time-sensitive deliveries.
Email contact@biofargo.com if you have any requirements.
